Scarica l'app Stockscreener
4.57
12.29%
0.50
Pre-mercato:
4.57
Lisata Therapeutics Inc Borsa (LSTA) Ultime notizie
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - Stock Titan
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital | LST - GuruFocus
Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs - Intellectia AI
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Asianet Newsable
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz
Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $36.7 million. - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Why Is Lisata Therapeutics Stock Gaining Today? - Benzinga
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - Benzinga
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson... - Proactive financial news
Lisata stock soars after Kuva Labs acquisition offer at 85% premium By Investing.com - Investing.com South Africa
Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Nigeria
Lisata Therapeutics Signs Binding Term Sheet With Kuva Labs - TradingView
Lisata To Be Acquired By Kuva Labs For $4/shr; Stock Soars Over 80% - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs for $4 per Share - Intellectia AI
Lisata Therapeutics (LSTA) Agrees to Acquisition by Kuva Labs - GuruFocus
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer - marketscreener.com
Kuva Labs to acquire Lisata Therapeutics for $4 per share - Investing.com
Lisata Therapeutics To Be Acquired By Kuva Labs For $4.00 Per Share In An All-Cash Tender Offer - TradingView
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
How Lisata Therapeutics Inc. (8NE) stock compares with top peersVolatility Index Analysis & Budget Friendly Growth - bollywoodhelpline.com
Aug Highlights: Will Lisata Therapeutics Inc stock benefit from M A - baoquankhu1.vn
Aug Closing: What is Lisata Therapeutics Incs market positionPortfolio Return Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Macro Review: How Lisata Therapeutics Inc. (8NE) stock compares with top peers2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
How Lisata Therapeutics Inc. (8NE) stock benefits from digital adoptionDollar Strength & High Win Rate Trade Alerts - ulpravda.ru
Why Lisata Therapeutics Inc. stock could benefit from AI revolutionMid Cap Growth Trends & Investment Portfolio Recommendations - Улправда
Lisata Ahead Of The Curve: Smart Partnerships, No Debt, And A Data-Rich Period Ahead - RTTNews
Lisata Therapeutics Q3 2025 Earnings Preview - MSN
Retail Trends: Can Lisata Therapeutics Inc 8NE stock deliver consistent EPS growth2025 Retail Activity & Daily Volume Surge Signals - moha.gov.vn
Buy Signal: How Lisata Therapeutics Inc 8NE stock reacts to fiscal policiesJuly 2025 Rallies & Smart Allocation Stock Reports - moha.gov.vn
Praxis Home Retail Limited At Critical Juncture Bounce or BreakdownUtilities Sector Analysis & Interactive Charts for Smarter Trading - earlytimes.in
Lisata Therapeutics (NASDAQ:LSTA) & Bioxytran (OTCMKTS:BIXT) Head-To-Head Comparison - Defense World
Lisata Therapeutics Inc 8NE Stock Analysis and ForecastStock Liquidity Analysis & Free Smart Trading Classes - earlytimes.in
PUMP Stock Analysis and ForecastVolume Profile Analysis & Exceptional Return Opportunities - earlytimes.in
Total debt per share of Lisata Therapeutics, Inc. – DUS:8NE - TradingView — Track All Markets
The next front against cancer: A Mugglehead roundup - Mugglehead Magazine
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):